More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapies through various clinical trial phases, including promising drugs such as Ravulizumab and AKB-9090. This robust pipeline reflects growing demand due to rising diabetes and critical care cases, with new targeted and regenerative treatments offering hope for better patient outcomes. Upcoming trial data and regulatory progress in 2026 will be critical for market advancement.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The FTSE 100 rose modestly by 21 points to 10,459, supported by consumer defensive stocks like Bunzl and AstraZeneca, despite heavy losses in miners and tech funds. US and Asian tech stocks, including AI and semiconductor firms, sold off sharply, wit...
The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biolog...
The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...
